Article
Cell Biology
Wen Pan, Jianyu Gu, Shihan Xu, Chunmei Zhang, Jinsong Wang, Songlin Wang, Junji Xu
Summary: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a serious complication in patients with osteoporosis or metastatic bone cancer. The study found that dietary nitrate, abundant in green vegetables, can protect against BRONJ-like lesions in mice. Nitrate intake increased plasma nitric oxide levels, reducing monocyte necrosis and inflammatory cytokine production. The findings suggest that dietary nitrate can inhibit monocyte necroptosis in BRONJ and promote bone remodeling after injury.
CELL PROLIFERATION
(2023)
Review
Immunology
Weidong Zhang, Ling Gao, Wenhao Ren, Shaoming Li, Jingjing Zheng, Shasha Li, Chunmiao Jiang, Shuying Yang, Keqian Zhi
Summary: Medication-related osteonecrosis of the jaw (MRONJ) is a rare but serious adverse drug effect, with hypotheses involving reduced bone remodeling, infection, inflammation, and bisphosphonates-induced immune dysfunction. Treatment with bisphosphonates disrupts mucosal and osteo immune homeostasis, impairing the body's ability to resist infection and repair from injury, contributing to the development of MRONJ.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Multidisciplinary Sciences
Milad Etemadi Sh, Farnaz Shooshtarian, Golnaz Tajmiri, MohammadSoroush Sehat
Summary: The present experiment aimed to assess the preventive effects of L-PRF on osteonecrosis of the jaw in rats. The application of L-PRF resulted in a significant reduction in osteonecrosis centers and the number of osteoclast cells. Therefore, it can be inferred that possible preventive effects on the clinical occurrence of osteonecrosis could be expected from the application of L-PRF.
Article
Multidisciplinary Sciences
Farnoosh Razmara, Mohammad Bayat, Sadegh Shirian, Ghazal Shabankare, Abdolreza Mohamadnia, Mostafa Mortazavi, Mohammad-Reza Alijani, Naghmeh Bahrami
Summary: The study found that using PRP + collagen scaffold showed better therapeutic effects compared to using scaffold alone, increasing bone mineralized density, number of osteoblasts, and new bone formation. In preventing BRONJ, PRP + collagen scaffold demonstrated better efficacy.
Article
Medicine, General & Internal
Gabor Kammerhofer, Daniel Vegh, Dorottya Banyai, Adam Vegh, Arpad Joob-Fancsaly, Peter Hermann, Zoltan Geczi, Tamas Hegedus, Kata Sara Somogyi, Bulcsu Bencze, Zita Biczo, Donat Huba Juhasz, Peter Zaborszky, Marta Ujpal, Mihaly Tamas Vaszilko, Zsolt Nemeth
Summary: This study aimed to evaluate the association between hyperglycemia and medication-related osteonecrosis of the jaw (MRONJ). The results showed a significant association between hyperglycemia and MRONJ, suggesting that hyperglycemia may lead to vascular anomaly and immune dysfunction, resulting in necrosis after tooth extraction.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Hironobu Hata, Kenji Imamachi, Michihiro Ueda, Masashi Matsuzaka, Hiroaki Hiraga, Toshihisa Osanai, Toru Harabayashi, Katsuya Fujimoto, Satoshi Oizumi, Masato Takahashi, Kazuhito Yoshikawa, Jun Sato, Yutaka Yamazaki, Yoshimasa Kitagawa
Summary: The study aimed to clarify the incidence of MRONJ and the corresponding survival rate of patients treated with zoledronic acid for different types of cancer. The results showed that patients with shorter survival times did not develop MRONJ, and dentists need to be aware of prognosis-related factors to predict MRONJ risk for effective dental management planning.
SUPPORTIVE CARE IN CANCER
(2022)
Review
Chemistry, Multidisciplinary
Krzysztof Wrobel, Maciej Sikora, Maciej Checinski, Maria Jas, Dariusz Chlubek
Summary: MRONJ is a condition that is becoming more common in dental and maxillofacial practice, requiring comprehensive, accessible, and up-to-date data. Besides bisphosphonates, angiogenesis inhibitors and anti-RANKL monoclonal antibodies can also increase the risk of the disease. Thorough physical examination, periodic correction of dental prostheses, and adequate preparation for oral procedures can prevent or minimize the risk of MRONJ.
APPLIED SCIENCES-BASEL
(2021)
Article
Dentistry, Oral Surgery & Medicine
Marcelo Vitale, Monica Grazieli Correa, Edilson Ervolino, Fabiano Ribeiro Cirano, Fernanda Vieira Ribeiro, Mabelle Freitas Monteiro, Marcio Zaffalon Casati, Suzana Peres Pimentel
Summary: This study evaluated the effect of resveratrol (RES) on the prevention of medication-related osteonecrosis of the jaws (MRONJ) in ovariectomized (OVX) rats treated with zoledronate (ZOL). The results showed that RES reduced tissue impairment caused by ZOL, but it could not prevent the occurrence of MRONJ.
Article
Endocrinology & Metabolism
Vanessa Costa de Sousa, Fatima Regina Nunes Sousa, Raquel Felipe Vasconcelos, Conceicao S. Martins, Amanda Pimentel Lopes, Nicholas Militao, Delane Viana, Karuza Alves, Renata Leitao, Gerly A. C. Brito, Virginia Girao, Paula Goes
Summary: Atorvastatin has a positive effect on bisphosphonate-induced osteonecrosis of the jaw in rats. It improves mucosal healing, increases viable osteocytes, reduces cell apoptosis, and decreases bone sequestration. It also modulates inflammation and improves bone vitality, metabolism, and structure.
Review
Toxicology
Bhumrapee Srivichit, Chanisa Thonusin, Nipon Chattipakorn, Siriporn C. Chattipakorn
Summary: Bisphosphonates are commonly used in the treatment of bone and joint diseases, but long-term use can lead to osteonecrosis. Osteonecrosis is characterized by cell death and impaired cell functions, with medication-related osteonecrosis of the jaw being the most concerning condition. In addition to surgical treatment, non-surgical interventions have been explored to mitigate bisphosphonate-induced osteonecrosis.
ARCHIVES OF TOXICOLOGY
(2022)
Article
Medicine, Research & Experimental
Yao Duan, Heija Li, Xiaohong Dong, Zhaoli Geng, Xinyi Xu, Yi Liu
Summary: This study investigated the role of VEGF in bisphosphonate-induced apoptosis and differentiation of osteoblasts. The results showed that VEGF can attenuate BP-induced apoptosis and differentiation of MC3T3 cells by regulating the NLRP3/caspase 1/GSDMD pathway.
EXPERIMENTAL AND THERAPEUTIC MEDICINE
(2022)
Article
Medicine, General & Internal
George Adrian Ciobanu, Adrian Camen, Mihaela Ionescu, Daniel Vlad, Cristina Maria Munteanu, Mircea Ionut Gheorghita, Cristian Virgil Lungulescu, Ionela Elisabeta Staicu, Elena Claudia Sin, Luminita Chivu, Razvan Mercut, Sanda Mihaela Popescu
Summary: This study aimed to establish the importance of risk factors in the development of MRONJ in cancer patients receiving zoledronic acid therapy. The analysis of 174 cancer patients revealed that treatment duration, chemotherapy, and hypertension were risk factors, while endocrine therapy and obesity were protective factors for MRONJ.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Dentistry, Oral Surgery & Medicine
Jie Liu, Nikos Mattheos, Chuanxi Deng, Cheng Su, Zekun Wang, Nanyu Luo, Hua Tang
Summary: Icariin benefits MRONJ by improving soft tissue wound area and empty bone lacuna ratio, while teriparatide activates RANKL expression and reduces bone necrosis area and empty lacuna ratio. These findings suggest potential therapeutic benefits for patients with MRONJ.
JOURNAL OF PERIODONTOLOGY
(2021)
Article
Endocrinology & Metabolism
Judith Everts-Graber, Daniel Lehmann, John-Patrik Burkard, Benoit Schaller, Brigitta Gahl, HansJoerg Haeuselmann, Ueli Studer, Hans-Rudolf Ziswiler, Stephan Reichenbach, Thomas Lehmann
Summary: This study aimed to determine the risk of ONJ in a real-world population, showing a higher incidence rate in patients receiving denosumab therapy compared to those receiving BPs, with previous BP therapy potentially being an additional risk factor for ONJ development.
JOURNAL OF BONE AND MINERAL RESEARCH
(2022)
Article
Cell Biology
Xin Chen, Weiwen Zhu, Rongyao Xu, Xin Shen, Yu Fu, Jie Cheng, Laikui Liu, Hongbing Jiang
Summary: This study revealed that long-term use of bisphosphonates such as Zoledronic Acid (ZA) may lead to Bisphosphonate-related Osteonecrosis of the Jaw (BRONJ) by inhibiting macrophage efferocytosis and promoting osteocytic apoptosis. Additionally, supplementing with geranylgeraniol (GGOH) can restore Rac1 homeostasis and rescue macrophage efferocytosis, potentially providing a new treatment approach for BRONJ.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Oncology
Victoria L. Parker, Matthew C. Winter, Elspeth Whitby, William A. E. Parker, Julia E. Palmer, John A. Tidy, Allan A. Pacey, Barry W. Hancock, Robert F. Harrison
Summary: The FIGO score and metastasis detection are higher using CT compared to CXR in GTN patients, which could potentially change treatment strategies for some patients. However, using CT does not significantly improve overall treatment outcomes, TNhCG, or the prediction of chemotherapy resistance compared to using CXR.
BRITISH JOURNAL OF CANCER
(2021)
Article
Oncology
Lynda Wyld, Malcolm W. R. Reed, Jenna Morgan, Karen Collins, Sue Ward, Geoffrey R. Holmes, Mike Bradburn, Stephen Walters, Maria Burton, Esther Herbert, Kate Lifford, Adrian Edwards, Alistair Ring, Thompson Robinson, Charlene Martin, Tim Chater, Kirsty Pemberton, Anne Shrestha, Alan Brennan, Kwok L. Cheung, Annaliza Todd, Riccardo Audisio, Juliet Wright, Richard Simcock, Tracy Green, Deirdre Revell, Jacqui Gath, Kieran Horgan, Chris Holcombe, Matt Winter, Jay Naik, Rishi Parmeshwar, Julietta Patnick, Margot Gosney, Matthew Hatton, Alastair M. Thomson
Summary: A propensity-matched study was conducted on breast cancer patients aged ≥ 70, showing that surgery is oncologically superior to primary endocrine therapy (PET) in most older women with early ER+ breast cancer. However, in some less fit, older patients, PET may be a safe treatment option.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Nicolo Matteo Luca Battisti, Matthew Q. Hatton, Malcolm W. R. Reed, Esther Herbert, Jenna L. Morgan, Michael Bradburn, Richard Simcock, Stephen J. Walters, Karen A. Collins, Sue E. Ward, Geoffrey R. Holmes, Maria Burton, Kate J. Lifford, Adrian Edwards, Thompson G. Robinson, Charlene Martin, Tim Chater, Kirsty J. Pemberton, Alan Brennan, Kwok Leung Cheung, Annaliza Todd, Riccardo A. Audisio, Juliet Wright, Tracy Green, Deirdre Revell, Jacqui Gath, Kieran Horgan, Chris Holcombe, Matthew C. Winter, Jay Naik, Rishi Parmeshwar, Margot A. Gosney, Alastair M. Thompson, Lynda Wyld, Alistair Ring
Summary: In older women with early breast cancer, the use of radiotherapy is influenced by age and recurrence risk, while geriatric parameters have limited impact on the type of surgery chosen. There is geographical variation in treatment patterns, with some fit older women with high-risk tumors not receiving radiotherapy and some older, low-risk patients receiving radiotherapy despite limited benefit. The impact on HRQoL is transient.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Oncology
R. Charles Coombes, Holly Tovey, Lucy Kilburn, Janine Mansi, Carlo Palmieri, John Bartlett, Jonathan Hicks, Andreas Makris, Abigail Evans, Sibylle Loibl, Carsten Denkert, Elisabeth Murray, Robert Grieve, Robert Coleman, Annabel Borley, Marcus Schmidt, Beate Rautenberg, Catarina Alisa Kunze, Uwe Rhein, Keyur Mehta, Kelly Mousa, Tessa Dibble, Xiao Lou Lu, Gunter von Minckwitz, Judith M. Bliss
Summary: The Randomized European Celecoxib Trial (REACT) evaluated the role of Celecoxib as an addition to conventional therapy for women with ERBB2-negative primary breast cancer. The study did not find evidence of a disease-free survival benefit for patients receiving 2 years of Celecoxib treatment compared to placebo. Longer-term treatment or higher doses of Celecoxib may need to be explored in further studies to determine potential benefits.
Article
Medicine, General & Internal
Milana A. Bergamino, Elena Lopez-Knowles, Gabriele Morani, Holly Tovey, Lucy Kilburn, Eugene F. Schuster, Anastasia Alataki, Margaret Hills, Hui Xiao, Chris Holcombe, Anthony Skene, John F. Robertson, Ian E. Smith, Judith M. Bliss, Mitch Dowsett, Maggie C. U. Cheang
Summary: This study aimed to identify biomarkers for the response of ER+/HER2+ breast cancers to AI treatment. The results showed that HER2-E is a standardized biomarker associated with poor response to AI and worse prognosis in ER+/HER2+ breast cancers. HRD, TP53 mutational score, and immune-tumor tolerance are predictive biomarkers for poor response to AI. Additionally, new molecular subtypes identify non-HER2-E tumors that do not respond to AI and have an increased risk of relapse.
Article
Oncology
Matthew Winter, Rob Coleman, Jessica Kendall, Carlo Palmieri, Chris Twelves, Sacha Howell, Iain MacPherson, Caroline Wilson, Kash Purohit, Jacqui Gath, Christine Taylor, Richard Eastell, Geraldine Murden, Sarah R. Brown, Emma Rathbone, Janet Brown
Summary: This study evaluates the safety and efficacy of the combination of capecitabine and Ra-223 in MBC patients with bone metastases. The results show that the combination therapy is safe and feasible, but no significant clinical or biochemical efficacy signals were observed.
JOURNAL OF BONE ONCOLOGY
(2022)
Article
Oncology
N. C. Turner, C. Swift, B. Jenkins, L. Kilburn, M. Coakley, M. Beaney, L. Fox, K. Goddard, I. Garcia-Murillas, P. Proszek, P. Hall, C. Harper-Wynne, T. Hickish, S. Kernaghan, I. R. Macpherson, A. F. C. Okines, C. Palmieri, S. Perry, K. Randle, C. Snowdon, H. Stobart, A. M. Wardley, D. Wheatley, S. Waters, M. C. Winter, M. Hubank, S. D. Allen, J. M. Bliss
Summary: The c-TRAK TN study is the first prospective study to evaluate the clinical utility of ctDNA testing in guiding therapy in TNBC. It found that TNBC patients had a high rate of metastatic disease on ctDNA detection. These findings have important implications for future trial design, emphasizing the importance of starting ctDNA testing early and using more sensitive and/or frequent ctDNA testing regimes.
ANNALS OF ONCOLOGY
(2023)
Article
Oncology
Victoria L. Parker, Bryony F. Cushen, Annie Hills, Kaveetha Kandiah, Julia E. Palmer, Kamaljit Singh, Barry W. Hancock, John A. Tidy, Matthew C. Winter
Summary: Dose individualization based on body surface area or weight does not affect the efficacy and relapse rate of chemotherapy in low-risk gestational trophoblastic neoplasia. Therefore, fixed dosing remains the preferred standard treatment in the UK.
GYNECOLOGIC ONCOLOGY
(2023)
Article
Oncology
Victoria L. Parker, Matthew C. Winter, John A. Tidy, Barry W. Hancock, Julia E. Palmer, Naveed Sarwar, Baljeet Kaur, Katie McDonald, Xianne Aguiar, Kamaljit Singh, Nick Unsworth, Imran Jabbar, Allan A. Pacey, Robert F. Harrison, Michael J. Seckl
Summary: This study compares the performance of the International Federation of Gynaecology and Obstetrics (FIGO) scoring system with other models in assessing chemoresistance in gestational trophoblastic neoplasia (GTN) patients. The study found that the other models outperformed FIGO in terms of diagnostic accuracy and positive predictive value. However, most models had significant discordance in patient classification, leading to potential undertreatment or overtreatment.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Review
Oncology
B. Hapuarachi, J. A. Tidy, C. Romanowski, K. Singh, S. Gillett, J. Ireson, M. C. Winter
GYNECOLOGIC ONCOLOGY
(2023)
Meeting Abstract
Oncology
Alistair E. Ring, Laura Moretti, Angelica Afshari-Mehr, Andrew M. Wardley, Lucy Kilburn, Bora Gurel, Iain R. MacPherson, Richard D. Baird, Sue Martin, Alex Pearson, Rebecca Roylance, Matthew Winter, Kathryn Dunne, Ellen Copson, Tamas Hickish, Peter Stephens, Russell J. Burcombe, Katrina Randle, Judith Bliss, Nicholas C. Turner
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Health Care Sciences & Services
Jane Ireson, Patricia Holch, Stephen Radley, Diana Greenfield, Matt Winter, John Tidy, Georgina Jones
QUALITY OF LIFE RESEARCH
(2022)
Article
Surgery
L. Wyld, M. W. R. Reed, K. Collins, M. Burton, K. Lifford, A. Edwards, S. Ward, G. Holmes, J. Morgan, M. Bradburn, S. J. Walters, A. Ring, T. G. Robinson, C. Martin, T. Chater, K. Pemberton, A. Shrestha, A. Nettleship, C. Murray, M. Brown, P. Richards, K. L. Cheung, A. Todd, H. Harder, K. Brain, R. A. Audisio, J. Wright, R. Simcock, F. Armitage, M. Bursnall, T. Green, D. Revell, J. Gath, K. Horgan, C. Holcombe, M. Winter, J. Naik, R. Parmeshwar, M. Gosney, M. Hatton, A. M. Thompson
Summary: The study found that using decision support interventions in older women with breast cancer increases knowledge of treatment options, facilitates shared decision-making, and alters treatment choices.
BRITISH JOURNAL OF SURGERY
(2021)
Article
Surgery
J. L. Morgan, A. Shrestha, M. W. R. Reed, E. Herbert, M. Bradburn, S. J. Walters, C. Martin, K. Collins, S. Ward, G. Holmes, M. Burton, K. Lifford, A. Edwards, A. Ring, T. Robinson, T. Chater, K. Pemberton, A. Brennan, K. L. Cheung, A. Todd, R. Audisio, J. Wright, R. Simcock, A. M. Thomson, M. Gosney, M. Hatton, T. Green, D. Revill, J. Gath, K. Horgan, C. Holcombe, M. C. Winter, J. Naik, R. Parmeschwar, L. Wyld
Summary: The study compared the quality-of-life outcomes in older women aged over 70 with operable breast cancer who underwent surgery or primary endocrine therapy, showing that primary endocrine therapy had less adverse impact on quality-of-life in various domains compared to major surgery, with effects largely resolved by 24 months.
BRITISH JOURNAL OF SURGERY
(2021)
Meeting Abstract
Oncology
Matthew Winter, Jessica Kendall, Sarah Brown, Emma Rathbone, Caroline Wilson, Sacha Howell, Chris Twelves, Carlo Palmieri, Anjana Anand, Iain MacPherson, Rob Coleman, Janet Brown